Selected Metal (Au, Ag, and Cu) Complexes of N-heterocyclic Ligands as Potential Anticancer Agents: A Review


Дәйексөз келтіру

Толық мәтін

Аннотация

Nitrogen-based organic heterocyclic compounds are an important source of therapeutic agents. About 75% of drugs approved by the FDA and currently available in the market are N-heterocyclic organic compounds. The N-heterocyclic organic compounds like pyridine, indole, triazoles, triazine, imidazoles, benzimidazoles, quinazolines, pyrazoles, quinolines, pyrimidines, porphyrin, etc. have demonstrated significant biological activities. These heterocyclic organic compounds also coordinate with various metal ions and form coordination compounds. Most of them have shown improved biological activities. The research on the metal complexes of these compounds reported their significant biological activities. N-heterocyclic-based metal complexes showed outstanding anticancer activities against different cancer cell lines, including VEGFR-2, HT-29, MDA-MB-231, MCF-7 K562, A549, HepG2, HL60, A2780, WI-38, Colo-205, PC-3, and other cancer cell lines. Some of these compounds showed better anticancer activity than cisplatin. In this review, we summarized the anticancer properties of N-heterocyclic-based gold (Au), silver (Ag), and copper (Cu) complexes and explored the mechanisms of action and potential structure-activity relationships (SAR) of these complexes. Our goal is to assist researchers in designing highly potent N-heterocyclic-based Au, Ag, and Cu complexes for the potential treatment of various cancers.

Авторлар туралы

Meshal Alshamrani

Department of Pharmaceutics, College of Pharmacy, Jazan University

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Al-Saidi, H.M.; Khan, S. A review on organic fluorimetric and colorimetric chemosensors for the detection of Ag(I) ions. Crit. Rev. Anal. Chem., 2022, 52, 1-18. doi: 10.1080/10408347.2022.2133561 PMID: 36251012
  2. Khan, S.; Alhumaydhi, F.A.; Ibrahim, M.M.; Alqahtani, A.; Alshamrani, M.; Alruwaili, A.S.; Hassanian, A.A.; Khan, S. Recent advances and therapeutic journey of schiff base complexes with selected metals (Pt, Pd, Ag, Au) as potent anticancer agents: A review. Anticancer. Agents Med. Chem., 2022, 22(18), 3086-3096. doi: 10.2174/1871520622666220511125600 PMID: 35546764
  3. Khan, S.; Chen, X.; Almahri, A.; Allehyani, E.S.; Alhumaydhi, F.A.; Ibrahim, M.M.; Ali, S. Recent developments in fluorescent and colorimetric chemosensors based on schiff bases for metallic cations detection: A review. J. Environ. Chem. Eng., 2021, 9(6), 106381. doi: 10.1016/j.jece.2021.106381
  4. Khan, S.; Muhammad, M.; Al-Saidi, H.M.; Hassanian, A.A.; Alharbi, W.; Alharbi, K.H. Synthesis, characterization and applications of schiff base chemosensor for determination of Cu2+ ions. J. Saudi Chem. Soc., 2022, 26(4), 101503. doi: 10.1016/j.jscs.2022.101503
  5. Mohammad Abu-Taweel, G.; Ibrahim, M.M.; Khan, S.; Al-Saidi, H.M.; Alshamrani, M.; Alhumaydhi, F.A.; Alharthi, S.S. Medicinal importance and chemosensing applications of pyridine derivatives: A review. Crit. Rev. Anal. Chem., 2022, 54(3), 599-616. doi: 10.1080/10408347.2022.2089839 PMID: 35724248
  6. Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K.K.; Jonnalagadda, S.B. A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules, 2020, 25(8), 1909. doi: 10.3390/molecules25081909
  7. Alrooqi, M.; Khan, S.; Alhumaydhi, F.A.; Asiri, S.A.; Alshamrani, M.; Mashraqi, M.M.; Alzamami, A.; Alshahrani, A.M.; Aldahish, A.A. A therapeutic journey of pyridine-based heterocyclic compounds as potent anticancer agents: A review (from 2017 to 2021). Anticancer. Agents Med. Chem., 2022, 22(15), 2775-2787. doi: 10.2174/1871520622666220324102849 PMID: 35331100
  8. Chiacchio, M.A.; Iannazzo, D.; Romeo, R.; Giofrè, S.V.; Legnani, L. Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents. Curr. Med. Chem., 2020, 26(40), 7166-7195. doi: 10.2174/0929867325666180904125400 PMID: 30182842
  9. Nural, Y.; Ozdemir, S.; Yalcin, M.S.; Demir, B.; Atabey, H.; Seferoglu, Z.; Ece, A. New bis- and tetrakis-1,2,3-triazole derivatives: Synthesis, DNA cleavage, molecular docking, antimicrobial, antioxidant activity and acid dissociation constants. Bioorg. Med. Chem. Lett., 2022, 55, 128453. doi: 10.1016/j.bmcl.2021.128453 PMID: 34801684
  10. Xu, H.; Lv, M. Developments of indoles as anti-HIV-1 inhibitors. Curr. Pharm. Des., 2009, 15(18), 2120-2148. doi: 10.2174/138161209788489168 PMID: 19519449
  11. Küçükgüzel, G.; Çikla-Süzgün, P. Recent advances bioactive 1,2,4-triazole-3-thiones. Eur. J. Med. Chem., 2015. 830-870.97 doi: 10.1016/j.ejmech.2014.11.033
  12. Gaba, M.; Mohan, C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions. Med. Chem. Res., 2015, 25, 173-210. doi: 10.1007/s00044-015-1495-5
  13. Kadhim, M.I.; Husein, I. Pharmaceutical and biological application of new synthetic compounds of pyranone, pyridine, pyrmidine, pyrazole and isoxazole incorporating on 2-flouroquinoline moieties. Syst. Rev. Pharm., 2020, 11(2), 679-684. doi: 10.5530/SRP.2020.2.98
  14. Faria, J.V.; Vegi, P.F.; Miguita, A.G.C.; dos Santos, M.S.; Boechat, N.; Bernardino, A.M.R. Recently reported biological activities of pyrazole compounds. Bioorg. Med. Chem., 2017, 25(21), 5891-5903. doi: 10.1016/j.bmc.2017.09.035
  15. Omar, A.; Saleh, N.M.; Abdel-Rahman, A.A-H.; El-Adl, K. Review article; Anticancer activities of some fused heterocyclic moieties containing nitrogen and/or sulfur heteroatoms. Al-Azhar. J. Pharm. Sci., 2020, 62(2), 39-54. doi: 10.21608/ajps.2020.118375
  16. Ma, D.L.; Wu, C.; Wu, K.J.; Leung, C.H. Iridium(III) complexes targeting apoptotic cell death in cancer cells. Molecules, 2019, 24(15), 2739. doi: 10.3390/molecules24152739
  17. Katsaros, N.; Anagnostopoulou, A. Rhodium and its compounds as potential agents in cancer treatment. Crit. Rev. Oncol. Hematol., 2002, 42(3), 297-308. doi: 10.1016/S1040-8428(01)00222-0 PMID: 12050021
  18. D’Amato, A.; Mariconda, A.; Iacopetta, D.; Ceramella, J.; Catalano, A.; Sinicropi, M.S.; Longo, P. Complexes of ruthenium(II) as promising dual-active agents against cancer and viral infections. Pharmaceuticals (Basel), 2023, 16(12), 1729. doi: 10.3390/ph16121729
  19. Zhang, C.; Xu, C.; Gao, X.; Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics, 2022, 12(5), 2115-2132. doi: 10.7150/thno.69424 PMID: 35265202
  20. Ma, D.L.; Wang, M.; Mao, Z.; Yang, C.; Ng, C.T.; Leung, C.H. Rhodium complexes as therapeutic agents. Dalton Trans., 2016, 45(7), 2762-2771. doi: 10.1039/C5DT04338G PMID: 26743935
  21. Jin, S.; Guo, Y.; Guo, Z.; Wang, X. Monofunctional platinum(II) anticancer agents. Pharmaceuticals (Basel), 2021, 14(2), 133. doi: 10.3390/ph14020133
  22. Tan, S.J.; Yan, Y.K.; Lee, P.P.F.; Lim, K.H. Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med. Chem., 2010, 2(10), 1591-1608. doi: 10.4155/fmc.10.234 PMID: 21426151
  23. Medici, S.; Peana, M.; Nurchi, V.M.; Lachowicz, J.I.; Crisponi, G.; Zoroddu, M.A. Noble metals in medicine: Latest advances. Coord. Chem. Rev., 2015, 284, 329-350. doi: 10.1016/j.ccr.2014.08.002
  24. Vechalapu, S.K.; Kumar, R.; Sachan, S.K.; Shaikh, K.; Mahapatra, A.D.; Draksharapu, A.; Allimuthu, D. Copper and manganese complexes of pyridinecarboxaldimine induce oxidative cell death in cancer cells. ACS Appl. Bio Mater., 2024, 7(10), 6696-6705. doi: 10.1021/acsabm.4c00854 PMID: 39240687
  25. Kalarani, R.; Sankarganesh, M.; Kumar, G.G.V.; Kalanithi, M. Synthesis, spectral, DFT calculation, sensor, antimicrobial and DNA binding studies of Co(II), Cu(II) and Zn(II) metal complexes with 2-amino benzimidazole Schiff base. J. Mol. Struct., 2020, 1206, 127725. doi: 10.1016/j.molstruc.2020.127725
  26. Sankarganesh, M.; V, Solomon R.; D Raja, J. Platinum complex with pyrimidine- and morpholine-based ligand: Synthesis, spectroscopic, DFT, TDDFT, catalytic reduction, in vitro anticancer, antioxidant, antimicrobial, dna binding and molecular modeling studies. J. Biomol. Struct. Dyn., 2021, 39(3), 1055-1067. doi: 10.1080/07391102.2020.1727364 PMID: 32036758
  27. Yellol, J.; Pérez, S.A.; Buceta, A.; Yellol, G.; Donaire, A.; Szumlas, P.; Bednarski, P.J.; Makhloufi, G.; Janiak, C.; Espinosa, A.; Ruiz, J.; Novel, C.; Novel, C. N-Cyclometalated benzimidazole ruthenium(II) and iridium(III) complexes as antitumor and antiangiogenic agents: A structure-activity relationship study. J. Med. Chem., 2015, 58(18), 7310-7327. doi: 10.1021/acs.jmedchem.5b01194 PMID: 26313136
  28. El-Boraey, H.A.; Emam, S.M.; Tolan, D.A.; El-Nahas, A.M. Structural studies and anticancer activity of a novel (N6O4) macrocyclic ligand and its Cu(II) complexes. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2011, 78(1), 360-370. doi: 10.1016/j.saa.2010.10.021 PMID: 21081283
  29. Shen, K.; Han, X.; Li, C.; Huang, G.; Mao, S.; Shi, X.; Wu, H. Synthesis, structure, electrochemical properties, and antioxidant activities of copper(II) and zinc(II) complexes with N,N-bis(N-ethyl-2-ylmethylbenzimidazol)allylamine ligand. J. Coord. Chem., 2018, 71(7), 980-990. doi: 10.1080/00958972.2018.1454593
  30. Kesavan, M.P.; V Kumar, G.G.; D R, J.; Anitha, K.; Karthikeyan, S.; Rajesh, J. DNA interaction, antimicrobial, antioxidant and anticancer studies on Cu(II) complexes of Luotonin A. J. Photochem. Photobiol. B, 2017, 167, 20-28. doi: 10.1016/j.jphotobiol.2016.11.024 PMID: 28039786
  31. Kanthecha, D.A.; Bhatt, B.S.; Patel, M.N. Synthesis, characterization and biological activities of imidazo1,2-apyridine based gold(III) metal complexes. Heliyon, 2019, 5(6), e01968. doi: 10.1016/j.heliyon.2019.e01968 PMID: 31294115
  32. Rubbiani, R.; Zehnder, T.N.; Mari, C.; Blacque, O.; Venkatesan, K.; Gasser, G. Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes. ChemMedChem, 2014, 9(12), 2781-2790. doi: 10.1002/cmdc.201402446 PMID: 25377650
  33. Trommenschlager, A.; Chotard, F.; Bertrand, B.; Amor, S.; Dondaine, L.; Picquet, M.; Richard, P.; Bettaïeb, A.; Le Gendre, P.; Paul, C.; Goze, C.; Bodio, E. Gold(i)–BODIPY–imidazole bimetallic complexes as new potential anti-inflammatory and anticancer trackable agents. Dalton Trans., 2017, 46(25), 8051-8056. doi: 10.1039/C7DT01377A PMID: 28594007
  34. Serratice, M.; Bertrand, B.; Janssen, E.F.J.; Hemelt, E.; Zucca, A.; Cocco, F.; Cinellu, M.A.; Casini, A. Gold(i) compounds with lansoprazole-type ligands: Synthesis, characterization and anticancer properties in vitro. MedChemComm, 2014, 5(9), 1418-1422. doi: 10.1039/C4MD00241E
  35. Turek, J.; Růžičková, Z.; Tloušťová, E.; Mertlíková-Kaiserová, H.; Günterová, J.; Rulíšek, L.; Růžička, A. 1,2,4‐Triazole‐based N ‐heterocyclic carbene complexes of gold(I): Synthesis, characterization and biological activity. Appl. Organomet. Chem., 2016, 30(5), 318-322. doi: 10.1002/aoc.3434
  36. Sankarganesh, M.; D Raja, J.; Sakthikumar, K.; Solomon, R.V.; Rajesh, J.; Athimoolam, S.; Vijayakumar, V. New bio-sensitive and biologically active single crystal of pyrimidine scaffold ligand and its gold and platinum complexes: DFT, antimicrobial, antioxidant, DNA interaction, molecular docking with DNA/BSA and anticancer studies. Bioorg. Chem., 2018, 81, 144-156. doi: 10.1016/j.bioorg.2018.08.006 PMID: 30121002
  37. Sankarganesh, M.; Raja, J.D.; Revathi, N.; Solomon, R.V.; Kumar, R.S. Gold(III) complex from pyrimidine and morpholine analogue Schiff base ligand: Synthesis, characterization, DFT, TDDFT, catalytic, anticancer, molecular modeling with DNA and BSA and DNA binding studies. J. Mol. Liq., 2019, 294, 111655. doi: 10.1016/j.molliq.2019.111655
  38. Sun, R.W.Y.; Lok, C.N.; Fong, T.T.H.; Li, C.K.L.; Yang, Z.F.; Zou, T.; Siu, A.F-M.; Che, C-M. A dinuclear cyclometalated gold(iii)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo. Chem. Sci. (Camb.), 2013, 4(5), 1979-1988. doi: 10.1039/c3sc21972k
  39. Cuin, A.; Massabni, A.C.; Pereira, G.A.; Leite, C.Q.F.; Pavan, F.R.; Sesti-Costa, R.; Heinrich, T.A.; Costa-Neto, C.M. 6-Mercaptopurine complexes with silver and gold ions: Anti-tuberculosis and anti-cancer activities. Biomed. Pharmacother., 2011, 65(5), 334-338. doi: 10.1016/j.biopha.2011.04.012 PMID: 21775091
  40. Maiore, L.; Cinellu, M.A.; Nobili, S.; Landini, I.; Mini, E.; Gabbiani, C.; Messori, L. Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties. J. Inorg. Biochem., 2012, 108, 123-127. doi: 10.1016/j.jinorgbio.2011.11.007 PMID: 22173093
  41. Ali, K.A.; Abd-Elzaher, M.M.; Mahmoud, K. Synthesis and anticancer properties of silver(I) complexes containing 2,6-bis(substituted)pyridine derivatives. Int. J. Med. Chem., 2013, 2013, 1-7. doi: 10.1155/2013/256836 PMID: 25386361
  42. Li, S.X.; Chen, Y.F.; Lu, Y.; Xu, S.H.; Liao, B.L. Synthesis, fluorescence, and anticancer activity of silver (I) complex based on 2-hydroxyquinoxaline ligand. Inorg. Nano-Met. Chem, 2020, 50(4), 315-320. doi: 10.1080/24701556.2020.1711772
  43. Aulakh, J.K.; Lobana, T.S.; Sood, H.; Arora, D.S.; Kaur, R.; Singh, J.; Garcia-Santos, I.; Kaur, M.; Jasinski, J.P. Silver derivatives of multi-donor heterocyclic thioamides as antimicrobial/anticancer agents: Unusual bio-activity against methicillin resistant S. aureus, S. epidermidis, and E. faecalis and human bone cancer MG63 cell line. RSC Advances, 2019, 9(27), 15470-15487. doi: 10.1039/C9RA01804B PMID: 35514853
  44. Stryjska, K.; Radko, L.; Chęcińska, L.; Kusz, J.; Posyniak, A.; Ochocki, J. Synthesis, spectroscopy, light stability, single-crystal analysis, and in vitro cytotoxic activity on HepG2 liver cancer of two novel silver(I) complexes of miconazole. Int. J. Mol. Sci., 2020, 21(10), 3629. doi: 10.3390/ijms21103629
  45. Li, W.; Zheng, M.; Shang, Y. Synthesis, characterization, thermal behavior, and antitumor activities of an Ag (I) complex based on 4-(2-hydroxyphenyl)-2-methylpyrimidine. J. Chem. Res., 2022, 46(3), 17475198221103541. doi: 10.1177/17475198221103541
  46. Alshamrani, M. Recent advances and therapeutic journey of pyridine-based Cu(II) complexes as potent anticancer agents: A review (2015–2022). J. Coord. Chem., 2023, 76(1), 1-19. doi: 10.1080/00958972.2022.2164190
  47. Dam, J.; Ismail, Z.; Kurebwa, T.; Gangat, N.; Harmse, L.; Marques, H.M.; Lemmerer, A.; Bode, M.L.; de Koning, C.B. Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo1,2-apyridine complexes and their potential anticancer activity. Eur. J. Med. Chem., 2017, 126, 353-368. doi: 10.1016/j.ejmech.2016.10.041 PMID: 27907874
  48. Geyl, K.K.; Baykov, S.V.; Kalinin, S.A.; Bunev, A.S.; Troshina, M.A.; Sharonova, T.V.; Skripkin, M.Y.; Kasatkina, S.O.; Presnukhina, S.I.; Shetnev, A.A.; Krasavin, M.Y.; Boyarskiy, V.P. Synthesis, structure, and antiproliferative action of 2-pyridyl urea-based Cu(II) complexes. Biomedicines, 2022, 10(2), 461. doi: 10.3390/biomedicines10020461 PMID: 35203671
  49. Anjomshoa, M.; Hadadzadeh, H.; Torkzadeh-Mahani, M.; Fatemi, S.J.; Adeli-Sardou, M.; Rudbari, H.A.; Nardo, V.M. A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines. Eur. J. Med. Chem., 2015, 96, 66-82. doi: 10.1016/j.ejmech.2015.04.020 PMID: 25874332
  50. Yuan, B.; Hu, J.; Guo, Y.; Zhang, J.; Zhang, S.; Zhang, K.; Zhao, J.; Hou, H. Nuclei DNA and mitochondria dual damages induced by thiosemicarbazone tripyridyl copper complexes with potential anti-tumor activity. Polyhedron, 2021, 203, 115225. doi: 10.1016/j.poly.2021.115225
  51. Pathaw, L.; Khamrang, T.; Selvakumaran, B.; Murali, M.; Arul Prakash, P.; M Jaabir, M.S.; Velusamy, M. Synthesis, structure, characterization and biological evaluation of 3‐substituted 1‐pyridin‐2‐ylimidazo1,5‐apyridine‐based copper(I)–phosphine complexes for anticancer drug screening. Appl. Organomet. Chem., 2021, 35(1), e6025. doi: 10.1002/aoc.6025
  52. Marzano, C.; Pellei, M.; Colavito, D.; Alidori, S.; Lobbia, G.G.; Gandin, V.; Tisato, F.; Santini, C. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand. J. Med. Chem., 2006, 49(25), 7317-7324. doi: 10.1021/jm0601248 PMID: 17149861
  53. Shaikh, S.A.; Bhat, S.S.; Hegde, P.L.; Revankar, V.K.; Kate, A.; Kirtani, D.; Kumbhar, A.A.; Kumbar, V.; Bhat, K. Synthesis, structural characterization, protein binding, DNA cleavage and anticancer activity of fluorophore labelled copper(ii) complexes based on 1,8-naphthalimide conjugates. New J. Chem., 2021, 45(35), 16319-16332. doi: 10.1039/D1NJ02696H
  54. Prosser, K.E.; Chang, S.W.; Saraci, F.; Le, P.H.; Walsby, C.J. Anticancer copper pyridine benzimidazole complexes: ROS generation, biomolecule interactions, and cytotoxicity. J. Inorg. Biochem., 2017, 167, 89-99. doi: 10.1016/j.jinorgbio.2016.11.006 PMID: 27915178
  55. Hou, L.; Jia, X.; Wu, Y.; Li, J.; Yao, D.; Gou, Y.; Huang, G. Aroylhydrazone Cu(II) complexes: Syntheses, crystal structures, and anticancer properties. J. Mol. Struct., 2021, 1239, 130469. doi: 10.1016/j.molstruc.2021.130469
  56. Rodić, M.V.; Leovac, V.M.; Jovanović, L.S.; Spasojević, V.; Joksović, M.D.; Stanojković, T.; Matić, I.Z.; Vojinović-Ješić, L.S.; Marković, V. Synthesis, characterization, cytotoxicity and antiangiogenic activity of copper(II) complexes with 1-adamantoyl hydrazone bearing pyridine rings. Eur. J. Med. Chem., 2016, 115, 75-81. doi: 10.1016/j.ejmech.2016.03.003 PMID: 27084495
  57. Pan, R.K.; Song, J.L.; Li, G.B.; Lin, S.Q.; Liu, S.G.; Yang, G.Z. Copper(II), cobalt(II) and zinc(II) complexes based on a tridentate bis(benzimidazole)pyridine ligand: Synthesis, crystal structures, electrochemical properties and antitumour activities. Transit. Met. Chem., 2017, 42, 253-262. doi: 10.1007/s11243-017-0129-9
  58. Choroba, K.; Machura, B.; Szlapa-Kula, A.; Malecki, J.G.; Raposo, L.; Roma-Rodrigues, C.; Cordeiro, S.; Baptista, P.V.; Fernandes, A.R. Square planar Au(III), Pt(II) and Cu(II) complexes with quinoline-substituted 2,2′:6′,2″-terpyridine ligands: From in vitro to in vivo biological properties. Eur. J. Med. Chem., 2021, 218, 113404. doi: 10.1016/j.ejmech.2021.113404 PMID: 33823390

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2025